Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial

医学 阿帕蒂尼 临床终点 内科学 无进展生存期 胎盘部位滋养细胞肿瘤 肿瘤科 化疗 临床研究阶段 临床试验 外科 怀孕 胎儿 遗传学 生物 胎盘
作者
Hongyan Cheng,Liju Zong,Yujia Kong,Xiaoyu Wang,Yu Gu,Wei Cang,Jun Zhao,Xirun Wan,Junjun Yang,Yang Xiang
出处
期刊:Lancet Oncology [Elsevier]
卷期号:22 (11): 1609-1617 被引量:53
标识
DOI:10.1016/s1470-2045(21)00460-5
摘要

Summary

Background

Treatment options for patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia are scarce. The synergistic antitumour effect of immunotherapy and antiangiogenic drugs has been shown in many solid tumours. This phase 2 trial evaluated the activity and safety of camrelizumab (PD-1 inhibitor) plus apatinib (VEGF receptor inhibitor) in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia.

Methods

This was a single-arm, open-label, phase 2 trial, done at a single tertiary health-care centre in Beijing, China. Women (18–70 years) with high-risk (International Federation of Gynecology and Obstetrics score ≥7) chemorefractory or relapsed gestational trophoblastic neoplasia who had received at least two lines of previously unsuccessful multidrug chemotherapy regimens and had an Eastern Cooperative Oncology Group performance status of 0–2 were eligible for inclusion. Patients received 4-week cycles of intravenous camrelizumab 200 mg every 2 weeks plus oral apatinib 250 mg once per day until disease progression or unacceptable toxicity. The primary endpoint was objective response rate assessed according to serum human chorionic gonadotrophin concentration. Activity and safety were analysed in all patients who received at least one dose of study drug. The study is ongoing, but recruitment is complete. The study is registered with ClinicalTrials.gov, NCT04047017.

Findings

Between Aug 7, 2019, and March 18, 2020, 20 patients enrolled; 19 (95%) were diagnosed with choriocarcinoma and one (5%) had placental site trophoblastic tumour. The median follow-up duration was 18·5 months (IQR 14·6–20·9). The objective response rate was 55% (95% CI 32–77); ten (50%; 95% CI 27–73) patients had complete response. The most common grade 3 treatment-related adverse events were hypertension (five [25%] patients), rash (four [20%] patients), neutropenia (two [10%]), leukocytopenia (two [10%]), and aspartate aminotransferase increase (two [10%]). One patient had a treatment-related serious adverse event (aspartate aminotransferase 19-times higher than the upper limit of normal). No grade 4 or 5 treatment-related adverse events were reported.

Interpretation

Camrelizumab plus apatinib showed promising antitumour activity and acceptable toxicity and could be a salvage therapy option for the treatment of high-risk chemorefractory or relapsed gestational trophoblastic neoplasia. Immune checkpoint inhibitors combined with chemotherapy for heavily-treated patients and upfront use of camrelizumab plus apatinib for patients with high-risk gestational trophoblastic neoplasia are under investigation in phase 2 trials.

Funding

National Natural Science Foundation of China, Jiangsu Hengrui Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
5秒前
Zzz完成签到,获得积分10
8秒前
9秒前
strong.quite完成签到,获得积分10
9秒前
meimei完成签到 ,获得积分10
10秒前
xy完成签到,获得积分10
10秒前
无痕完成签到,获得积分10
12秒前
13秒前
14秒前
慧海拾穗完成签到 ,获得积分10
14秒前
pooh完成签到,获得积分10
14秒前
专注的夜蓉完成签到,获得积分10
16秒前
17秒前
zycdx3906完成签到,获得积分20
18秒前
乐乐发布了新的文献求助10
18秒前
19秒前
19秒前
20秒前
隐形曼青应助射天狼采纳,获得10
21秒前
彭于晏应助平淡的邪欢采纳,获得10
21秒前
努力勤奋完成签到,获得积分10
24秒前
bryceeluo应助zycdx3906采纳,获得10
25秒前
25秒前
28秒前
科研的猫发布了新的文献求助10
33秒前
阿莫西林胶囊完成签到,获得积分10
34秒前
eric完成签到 ,获得积分10
36秒前
37秒前
SciGPT应助pooh采纳,获得10
38秒前
从容灭绝应助chai采纳,获得10
39秒前
40秒前
轻松的芯完成签到 ,获得积分10
41秒前
小白完成签到,获得积分10
42秒前
情怀应助王楠采纳,获得10
43秒前
starry发布了新的文献求助10
43秒前
yueyueyahoo发布了新的文献求助20
43秒前
44秒前
JamesPei应助只只采纳,获得10
45秒前
46秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 800
Ethnicities: Media, Health, and Coping 700
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3086063
求助须知:如何正确求助?哪些是违规求助? 2738975
关于积分的说明 7552581
捐赠科研通 2388790
什么是DOI,文献DOI怎么找? 1266693
科研通“疑难数据库(出版商)”最低求助积分说明 613547
版权声明 598591